Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mapatumumab - Human Genome Sciences

Drug Profile

Mapatumumab - Human Genome Sciences

Alternative Names: Death-receptor-4-monoclonal-antibody; DR4 mAB; DR4-monoclonal-antibody; HGS-1012; HGS-ETR1; TRAIL-R1 monoclonal antibody; TRAIL-receptor-1-monoclonal-antibody; TRM-1

Latest Information Update: 15 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TNF related apoptosis inducing ligand stimulants; TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer
  • Discontinued Colorectal cancer; Liver cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 15 Apr 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Monotherapy) in Canada (IV)
  • 15 Apr 2021 Discontinued - Phase-II for Colorectal cancer (Monotherapy) in Germany (IV)
  • 15 Apr 2021 Discontinued - Phase-II for Liver cancer (Combination therapy, First-line therapy, Late-stage disease) in Ukraine, Russia, Romania, Puerto Rico, Poland, Germany, USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top